Expanding the clinical trial portfolio for lung cancer

Matthew Hatton, MSc, MBChB, MRCP, FRCP, FRCR, Weston Park Hospital, Sheffield, UK, is the chair of the NCRI Lung Clinical Studies Group. The group’s remit is to develop the trial portfolio for lung cancer in order to cover areas that are not particularly well covered by the pharmaceutical industry. Such areas include screening, early diagnosis, radiotherapy, surgery, supportive care, and palliative care. The goal is that, ultimately, clinical trials become an option for all lung cancer patients as part of their disease management and treatment.

Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.

Share this video